



BIOMARKERS IN BREAST CANCER

JOANNE MORTIMER, MD

Vice Chair, Medical Oncology and Therapeutics Director, Women's Cancers Program Baum Professor of Women's Cancers

Biomarkers in breast cancer

- Traditional ○Nodal status oTumor Size oTumor grade ◦ER, PR ○HER2 Molecular oOncotype ○MammaPrint
- Functional Imaging


 Estrogen
 HER2

Predictive Markers ○ESR1 ○ER, PR ○HER2 ○PIK3/akt Potential Targets oER, PR ○HER2 oTrop 2 **OHER3**

🛣 Cityof Hope.




810,587 women with operable invasive cancers from SEER with mean f/up of 94.2 months



Hwang, Br Ca Res and Treat 202;179:139-151

810,587 women with operable invasive cancers from SEER with mean f/up of 94.2 months



Hwang, Br Ca Res and Treat 202;179:139-151



Significance of PR in Stage IV ER+ Breast Cancer Response to Tamoxifen

		% Response with		
		PgR Level (fmol/mg)		
Patient Subset	Number	<10	10-99	<u>></u> 100
All	342	43	53	64
ER < 50 fmol/mg	120	31	42	59
ER≥50 fmol/mg	222	53	59	66


Ravdin, JCO 1992;10: 1284-1291

Nex Generation Sequencing directs subsequent therapy in HR+ disease

CEY 📀 Approved in Indication 😑 Approved in Other Indication 🔋 Lack of Response				
Detected Alte	ration(a) / Biomarker(a)	Associated FDA-approved therapies	Clinical Trial Availability	% ofDNA or Amplificati
PIK3CA	H1047R	Alpelialb+fulvestrant, Capivasertib+fulvestrant	Yes	1.2%
AKT1	E17K	Capivasertib+fulvestrant	Yes	0.5%
АТМ	D2507D	Synonymous Alteration ⁵	No (Synonymous) ⁵	1.0%
BRCA2	<u>H595P</u>	None (VUS) [§]	None (VUS) [§]	0.6%
RIT1	<u>R106Q</u>	None (VUS) [§]	None (VUS) [§]	0.6%



PI3K/AKT/mTOR pathway




Baselga, NEJM 2012;366:520-526 Andre, NEJM 2019;380:1929-1940 Turner, NEJM 2023;388:2058-2070

ESR1 mutations

- Are seldom present at diagnosis
- Likely to occur as a result of the "pressure" of therapy
- May predict for lack of efficacy of Ais
- Direct therapy to SERMs and SERDS



ESR 1 mutation






Functional Imaging

- Information about biologic activity
- Provides information about the entire patient
- Limited by lesion size






16 α **[18F]**fluoro-17 β -estradiol





Relationship Between ¹⁸F-FES-PET Uptake and Quantitative ER







Wahl. Radiology 169;45-48, 1988



FES PET imaging ¹⁸FDG



¹⁸FES



Summary of ¹⁸FES-PET Use


- Determine estrogen dependence when bx not possible
- Predict lack of response to endocrine therapy
- Identifies low grade disease
- Not helpful with liver metastases
- Not reliable in pts on SERD


Her2-Positive Breast Cancer

Prognostic significance of HER2/*Neu* oncoprotein expression in nodepositive breast cancer



888 breast cancer from 1980-1986 (Quebec)






Tetu, Cancer 1994;73:2359-2365

🔣 Cityof Hope.

HER2 as a target




[Proliferation, survival, invasion, angiogenesis]





Singh, British J of Ca 2014;111:1888-1898

HER2 Assessment by Immunostaining




Positive 3+






Negative 0




Equivocal 2+



Hicks, Lab Medicine 2011:42:459-67

We have utilized ⁶⁴Cu-DOTA-Trastuzumab to image women with advanced breast cancer with HER2 1+, 2+, 3+




IHC 1+

IHC 3+

Mortimer, J Nucl Med 2018;59:38-43

Tumor uptake of ⁶⁴Cu-DOTA-Trastuzumab is highly correlated with HER2 gene amplification




CONCLUSION: Gene amplification explains high-side variability of tumor uptake.

REMAINING QUESTION: What causes the variability about the regression line?


E.g., the 2 patients with avg # of HER2 copies closest to 15 vary nearly 3-fold in mean uptake, which could well make the difference between response & non-response.



⁶⁴cu-DOTA-trastuzumab PET Imaging ,to predict response to TDM1 in Advanced HER2+ Breast Cancer




64Cu-DOTA –trastuzumab PET to predict response to TDM1 in advanced breast cancer




Mortimer, J Nucl Med 2022;63:1145-48

Mixed Trastuzumab Uptake and Response




Mortimer, J Nuc Med 2019;60:23

⁶⁴cu-DOTA-trastuzumab PET Uptake in brain




 \rightarrow vessels

Currently studying ⁶⁴cu-DOTA-trastuzumab PET to predict for CNS response to trastuzumab-deruxtecan






TROP2 and Cancer





Liu, Pharm and Ther 2022: 108296


Sacituzumab is approved in advanced HR+/HER2- and TNBC



Trop-2, trophoblast cell surface antigen 2.



Sacituzumab as second line therapy in Triple Negative Breast Cancer





Stratification factors

- Number of prior therapies (2-3 vs >3)
- Geographic region (North America vs Europe)
- Presence/absence of known brain metastases (Yes/No)



Sacituzumab as second line therapy in Triple Negative Breast Cancer






O'Shaughnessy, Br Ca Res and Treat 2022;195:127-139




Response by TROP2 expression from ASCENT trial of sacituzumab govitecan versus chemotherapy in TNBC




Bardia, Annals of Oncol 2021;32: 1148-1156

TROP2 expression in normal skin








Ito, Int J Mol Sci 2021;22: 7706



Antibody Drug Conjugates in Breast Cancer

	Target		
Payload	HER2	TROP2	HER3
Maytansine Derivative	TDM1		
Deruxtecan	TDXd	Datopotomab	Patritumab
SN38		Sacituzumab	

Patritumab deruxtecan



Yonesaka, Cancers 2021;13(5), 1047



Patritumab Deruxtecan

10/26/21 PREtreatment



🛣 Cityof Hope.

11/23/21 PRE-Cycle 2



1/4/22 PRE-Cycle 3





Patritumab deruxtecan Phase I/II study in metastatic breast cancer

	HR+/HER2-	TNBC	HER2+
Number	113	53	14
ORR	30.1%	22.6%	42.9%
PFS	7.4 months	5.5 months	11 months

Dose Limiting Toxicity - GI and Hematologic Responses seen in high and low HER3 expression



Olaparib in MBC with Germline mutations TBCRC 048

	g <i>PALB2</i> Cohort 1a (n=24)	s <i>BRCA</i> Cohort 2a (n=30)
Age – median (range)- yrs	53 (26-86)	63 (28-86)
Subtype* ER+ HER2-neg TNBC HER2+	79% 13% 8%	77% 13% 10%
BRCA1 BRCA2		50% 50%
# lines chemo in metastatic setting- (median, range)	0 (0-2)	1 (0-3)
Prior platinum	4%	10%

Gene	ORR (90% CI)
g <i>PALB2</i> (n=11)	82% (48%-98%)
s <i>BRCA</i> (n=16)	50% (25%-75%)
<i>ATM, CHEK2</i> (n=18)	0%

* Subtype of primary tumor

Thoughts about biomarkers in breast cancer

- Important in directing therapy
- May provide prognostic information
- May predict for toxicity
- Limited by sampling
- Functional imaging provides pharmacokinetic information

 In assessing response, the threshold for efficacy or lack thereof is likely to be different for every agent and disease site

